Article citationsMore>>

Rivera, V.M., Kreisberg, J.I., Mita, M.M., Goldston, M., Knowles, H.L. and Herson, J. (2005) Pharmacodynamic study of skin biopsy specimens in patients (patients) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. American Society of Clinical Oncology, 23, 3033.

has been cited by the following article:

• TITLE: Effect of deforolimus and VEGF on angiogenesis in endometrial stromal cells following three-dimensional culture

  AUTHORS: Jafar Ai, Somayeh Ebrahimi, Armin Ai, Roya Karimi, Naghmeh Bahrami

  KEYWORDS: Endometrial Stromal Cells; Endometrium; 3-D culture; Deforolimus; VEGF

  JOURNAL NAME: Stem Cell Discovery, Vol.3 No.1, January 11, 2013

  ABSTRACT: The presence of endometrial tissue outside of the uterine cavity is named endometriosis and is the most common gynecologic disorder in women. Determining the inhibitory effect of a Deforolimus on angiogenesis in a three-dimensional (3-D) culture of human endometrial stromal cells (hEnCs) in vitro. The important mechanism in the pathogenesis of endometriosis is angiogenesis, and deforolimus has been shown to have anti-angiogenic activity. This was an in vitro study of human endometrial stromal cells in 3-D culture of fibrin matrix. Endometrial stromal cells isolated and placed in a 3-D fibrin matrix culture system for angiogenesis with VEGF and inhibit angiogenesis by deforolimus. Finally these cells analyzed by CD31 antibodies. After 3 weeks, in cells treated with VEGF, endothelial cell branching was observed and rudimentary capillary-like structures formed. In the presence of 5μM of deforolimus, angiogenesis was reduced. The deforolimus were shown to be effective in inhibiting the mechanisms of angiogenesis.